Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is there any post that summarizes upcoming catalysts / milestones for the ZTE and GOOG case?
Thank you
Is $1 ++ a slam dunk leading up to September Scotus hearing? Thoughts? Bought 120000 for a trade but thinking of adding more
Thanks
MEIP:NASDAQ $1.72, $2 per share cash excellent Phase 2 AML results
MEIP is the cheapest biotech on NASDAQ imo
Incredible Phase 2 results for AML Phase 3 later this year
Trades BELOW cash value
SNSS had $500 MM market cap based on Phase 3 AML drug
Very favorable writeup on SA this week: multiple catalysts
Conference on Tuesday
What news is that?
SPHS $1.08 + $.20 has room to run
Prostate cancer is treatable with surgery but unfortunately leaves many side effects because the treatment targets the entire prostate, and can cause incontinence and impotence.
SPHS has a HUGE potential market because it targets ONLY the cancerous area within the prostate, avoiding the side effects.
IMO a $50 million market cap ($3.50 per share) is still DIRT CHEAP for the potential market for this stock.
ISNS moving, 5 million float, rail safety play, also much better outlook, booming backlog and return to profit forecast.
Thanks, although the public record clealy indicates fireworks are coming so your not ntelling us anything new.
UNPRECEDENTED: 1.1 million float stock with FDA approved product leading the fight on biggest epidemic of our generation.
I buy NASDAQ stocks and rarely buy OTC, but when I found SIMH I knew it was special and unprecedented. There have been OTC stocks that have gone from pennies to $10 in a few days, that can happen when there are few shares in the float in the midst of a market frenzy.
October 2 PR: Interest from HUNDREDS OF HOSPITALS
Gee, do you think we will see any orders?
Tiny 18 million float, and $3 million market cap compared to $50 million plus for every other Ebola stock I follow. Ebola crisis will be front page news for months. I agree this will be $1 in short
order. LOTS of traders who made fat profits in other Ebola stocks searching for next Ebola runner.
SIMH would be $5 if it traded at same market cap as IBIO. Not saying it will, just want to give some perspective on how cheap this is.
Hard to imagine a better opportunity than this. A dirt cheap low float Ebola stock with actual orders that has just been discovered.
looking for $.50 next week.
great see ya at $1.20
Scope of ZTE case versus GOOGLE case
Anyone Have a good sense how GOOG case compares to ZTE case in terms of validity of patents, size of damages, where we are in process?
Any idea when they will decide if VRNG gets En Banc hearing?
If the market was perfectly efficienct, I couldn't have made 9 million in the last 5 years. anyway good luck, this is going in circles.
I'm not expecting anything, just refuting your initial assertion that the price is based on known information, its pricing VRNG on expecttions.
I know about efficient market theory, took my MBA.
exactly my point the market expecting small settlement, but if there is unexpectedly a large settlement would not be priced in because it's not public info.
While I agree that the settlement will probably be modest, I don't agree with your view that if the settlement was large, it would be reflected in the price.
Similar to an FDA decision on a drug, too few people would be aware of the derails in advance to make a difference in the price before the news goes public.
Belkin has $1 billion in revenue. Patent settlements take into account the benefit the infringing party gets from the patent. I have no idea how the benefit Belkin gets from the patents compares to ADT, but my point is it just because it's the same patent doesn't mean the settlement will be similar.
If these patents have little value, do you think there is still any reason to hold VRNG as an investment for significant gains in the short term (next few months) ?
except prison break is premised on actual facts and events, there are no facts to support an XXII price before $5.
OXGN moving pre market on news yestetday that Phase 2 ovarian cancer drug met endpoint look ing for $3 today
OXGN DD post, trades at cash value
Their key catalyst is that they present the full data NCI/GOG data in the September. News is expected at ESMO 2014 Congress Sep 26 - 30 2014. $OXGN is also listed on the ETA (European Thyroid Association) 2014 meeting in early September. http://t.co/cLLQ6RamWu . ESMO 2014 will follow that conference is the key GOG full data release.
The company has a market cap of only 39m. It has an O/S of 15.3m and a float of 13.4m. Company just did a recent financing at $2.96/share. OXGN has a 52wk low of $1.96 & a 52wk high of $5.40.
Oxigene Corporate Presentation May 2014..$OXGN http://bit.ly/1jfm32B
OXGN..Wainright assumes a buy on 6/26/14. http://www.smarteranalyst.com/2014/06/26/h-c-wainright-assumes-buy-as-oxigene-displays-tremendous-potential-upside/
OXiGENE, Inc. Announces $16 Million At-The-Market Registered Direct Offering. This offering was done at $2.96/share.
http://finance.yahoo.com/news/oxigene-inc-announces-16-million-130000685.html
@adamfeuerstein: $OXGN Surprises With Positive Ovarian Cancer Study Success —> http://t.co/67O3wta2B4
@FierceBiotech: Oxigene roars back to life on positive ovarian cancer study. http://t.co/fI9oX3ItGX
OXiGENE, Inc. Discusses Q4 2013 Results (Webcast) http://t.co/JtSc00IswU $OXGN Listen to the 4 minute mark on the details of the results. The 6:45 mark discusses full data presentation soon in H2 2014.
Oxigene Discusses Q1 2014 results:
http://seekingalpha.com/article/2196453-oxigenes-oxgn-ceo-peter-langecker-on-q1-2014-results-earnings-call-transcript
“I’d also like to mention that given the positive developments in the first quarter, we are increasingly excited about our future prospects at OXiGENE. Our cash position is stronger, and we have significant new Phase II data that opens up opportunities for future clinical development and exploring potential partnerships.”
OXGN-Zybrestat
http://www.oxigene.com/product-development/zybrestat
$OXGN..12.43 % of float is sold short
NLST starting to move still dirt cheap at $1.27. Could move to $4 in a few weeks like VRNG and SPEX. In May conference call CEO said monertization of intellectual property will occur shortly. NLST has hundreds of patents on hypcloud and has lawsuits against many heavyweights like Google and Diablo. There is a reason a heavyweight like Fortress invested.
RMGN $1.35 + $.20 4 MM float
RMGN is next NEWL.
-Is a U.S. based stock
-Was $4 a few months ago
-Drop was huge overreaction to seasonally weakest Q1 results, good balance sheet, no debt, will be cash flow positive in second half.
RMGN 4 million float $1.35 + $.20
http://finance.yahoo.com/q?s=RMGN
Low float stocks like NEWL and IGC have been flying RMGN is much better, 4 million float was $10 earlier this year.
RMGN has great financials, no debt, turning EBITDA positive in second half.
If you missed PLUG ($.08 to $11) check out ZBB. ZBB would be $30 if valued like PLUG and PLUG has a much larger potential market, bidding as subcontractor on many billion dollar contacts.
This is nothing next week we will see 2 MM volume days with $.50 price rise.
The beauty of this is tiny float and huge news.
SMTX is a no brainer at $1.82. Huge insider buys last week, 15 million shares OS, has slashed costs and announced major contract wins, said margings will improve.
Reported 1.7 MM EBITDA last quarter, I expect $12 million for the year, at 10 x forward EBITDA SMTX would be $8.
http://finance.yahoo.com/news/smtc-reports-first-quarter-results-120000154.html
SMTX is a no brainer at $1.82. Huge insider buys last week, 15 million shares OS, has slashed costs and announced major contract wins, said margings will improve.
Reported 1.7 MM EBITDA last quarter, I expect $12 million for the year, at 10 x forward EBITDA SMTX would be $8.
http://finance.yahoo.com/news/smtc-reports-first-quarter-results-120000154.html
ADHXF up 20% to $1.25, presenting 2 Phase 3 results at ASCO.
With 7 million float could have lots more upside. Very good preliminary results. Also trades on Toronto Exghange as AHX.TO so has good liquidity.
Sodium Thiosulfate (STS) Phase 3 Clinical Study Update
Adherex Announces Sodium Thiosulfate Clinical Study Update
~ Data have been submitted to ASCO 2014~
Adherex’s collaborator the Children’s Oncology Group (COG) posted top-line results from a Phase III trial of Adherex’s lead candidate STS to clinicaltrials.gov last week. The data are incomplete and no statistical analysis was performed. A full analysis of secondary endpoints such as event free survival and overall survival was not posted. Any interpretation should be limited until Adherex reports the full data, which is expected at the American Society of Clinical Oncology (ASCO) meeting in June 2014.
Posted Data, though Incomplete, is Encouraging. According to the posted results, the data regarding the frequency of patients with hearing loss is encouraging, and may support the primary endpoint after a full statistical analysis. The primary endpoint of the trial is hearing protection in pediatric oncology patients undergoing platinum-based chemotherapy.
The posted data show that out of 56 patients in the cisplatin arm of the study, 31 (55%) experienced hearing loss. For the 49 patients treated with STS and cisplatin, 14 (29%) experienced hearing loss. Information posted on the website is incomplete and final results may differ from those presented.
This will go to $2.50 - $3 range by ASCO, then they will announce financing, goes without saying tney will not do it now.
SPEX was $8 a few weeks ago no rebounding at $2.60, Insider buying at $3.15
http://seekingalpha.com/article/2127363-spherix-playing-the-patent-game?source=yahoo
Patent plays have been one of the hottest sectors SPEX has tiny float.
APPY FDA submission any day now
Huge market for appendicitis test
Took position at $2.54
http://finance.yahoo.com/news/venaxis-announces-positive-top-line-110000071.html
VELT is now debt free wIth China Middle East South america and TAX losses that could be worth $2 per share
Your better off not to know that now as it may trade up on speculation. Of they announced sharehilders get 0 then stock price goes to 0.
CNDO $1.67, $3 per share cash, no debt, compelling buy IMO
Looks like the drop was tax loss selling, October 31 is last day for institutions to sell for tax losses
too bad it went down
Wull go back up